Literature DB >> 17221305

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.

Stephan A Veltkamp1, Jetske M Meerum Terwogt, Michel M van den Heuvel, Hester H van Boven, Jan H M Schellens, Sjoerd Rodenhuis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17221305     DOI： 10.1007/s10637-006-9030-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  6 in total

1.  Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project.

Authors:  Steven M Belknap; Timothy M Kuzel; Paul R Yarnold; Nicholas Slimack; E Allison Lyons; Dennis W Raisch; Charles L Bennett
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

2.  Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.

Authors:  Kirsten M Leu; Leo J Ostruszka; Donna Shewach; Mark Zalupski; Vernon Sondak; J Sybil Biermann; Julia Shin-Jung Lee; Carol Couwlier; Krisinda Palazzolo; Laurence H Baker
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

3.  High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.

Authors:  Charalambos Kouroussis; Dimitris Mavroudis; Stylianos Kakolyris; Argyro Voloudaki; Konstantinos Kalbakis; John Souglakos; Sophia Agelaki; Konstantinos Malas; Vassiliki Bozionelou; Vassilis Georgoulias
Journal:  Lung Cancer       Date:  2004-06       Impact factor: 5.705

4.  Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

Authors:  Jacques-Olivier Bay; Isabelle Ray-Coquard; Jérôme Fayette; Serge Leyvraz; Stephane Cherix; Sophie Piperno-Neumann; Christine Chevreau; Nicolas Isambert; Etienne Brain; Georges Emile; Axel Le Cesne; Angela Cioffi; Fabrice Kwiatkowski; Jean-Michel Coindre; Nguyon Binh Bui; Frédéric Peyrade; Nicolas Penel; Jean-Yves Blay
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396

5.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Authors:  Martee L Hensley; Robert Maki; E Venkatraman; Gennifer Geller; Meghan Lovegren; Carol Aghajanian; Paul Sabbatini; William Tong; Richard Barakat; David R Spriggs
Journal:  J Clin Oncol       Date:  2002-06-15       Impact factor: 44.544

6.  SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.

Authors:  P A Vasey; R Atkinson; R Osborne; D Parkin; R Symonds; J Paul; L Lewsley; R Coleman; N S Reed; S Kaye; G J S Rustin
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640
  6 in total
  3 in total

Review 1.  Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine.

Authors:  Silvia Antolín; Lourdes Calvo; Diana Dopico; María Quindós; Margarita Reboredo; Alberto Carral
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Authors:  Martee L Hensley; John A Blessing; Robert Mannel; Peter G Rose
Journal:  Gynecol Oncol       Date:  2008-06       Impact factor: 5.482

3.  Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Authors:  Martee L Hensley; John A Blessing; Koen Degeest; Ovadia Abulafia; Peter G Rose; Howard D Homesley
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.